文献速递泌尿生殖与妇科肿瘤放疗

局部晚期宫颈癌放化疗联合磁共振引导近距离放疗国际研究中生物标志物表达与临床结局:BIOEMBRACE研究

Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer: BIOEMBRACE.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-07-26

BIOEMBRACE研究纳入264例接受放化疗和磁共振引导近距离放疗的局部晚期宫颈癌患者,分析p16、PD-L1和L1CAM表达与疗效的关系。p16阴性及MRI坏死独立预测近距离放疗反应差,PD-L1>1%和L1CAM≥50%分别独立影响5年局部控制和盆腔控制。

要点

  • p16阴性和MRI坏死独立预测近距离放疗时HR-CTV≥40cc。
  • PD-L1>1%与5年局部控制和盆腔控制降低相关。
  • L1CAM≥50%是5年盆腔控制的独立影响因素。

核心结论

  • p16阴性和MRI肿瘤坏死与放化疗反应差独立相关,PD-L1>1%和L1CAM≥50%分别对局部控制和盆腔控制有独立影响,提示生物标志物表达可能影响结局,需进一步验证。

研究设计与样本

  • 2018年至2021年间,8个EMBRACE-I中心提供肿瘤组织用于p16、PD-L1和L1CAM免疫组化检测,共纳入264例局部晚期宫颈癌患者。
  • 分析生物标志物及临床病理因素对近距离放疗反应差(HR-CTV≥40cc)和5年局部控制、盆腔控制、无病生存的预测作用,并探讨p16、PD-L1与放疗剂量(HR-CTV D90)及疾病结局的交互作用,采用单因素和多因素分析。

主要发现

  • HR-CTV D90中位值为89 Gy(86-95)。
  • p16阳性、PD-L1>1%和L1CAM≥10%分别见于86.6%、20.1%和17.8%的患者。
  • p16阴性(OR 2.0;95%CI 1.0-5.7;P=.04)和MRI坏死(OR 2.1;95%CI 1.1-4.3;P<.02)独立预测HR-CTV≥40cc,国际妇产科联盟分期和肿瘤宽度>5cm亦为预测因素。
  • PD-L1>1%与5年局部控制降低相关(82% vs 94%;P=.02)和盆腔控制降低相关(79% vs 89%;P=.02)。
  • HR-CTV D90<85 Gy与p16阳性患者5年局部控制较差相关,尤其当PD-L1共表达时;多因素分析中,PD-L1>1%是5年局部控制的唯一独立因素(HR 3.3;P=.04),L1CAM≥50%是盆腔控制的独立因素(HR 5.5;95%CI 1.3-23.3;P=.02)。

局限性

  • 原文结论指出需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BIOEMBRACE was designed to study the impact of biomarkers in addition to clinicopathological factors on disease outcomes in patients treated with chemoradiation and magnetic resonance imaging (MRI)-guided brachytherapy (BT) for locally advanced cervical cancer in the EMBRACE study. METHODS AND MATERIALS: Between 2018 and 2021, 8 EMBRACE-I sites contributed tumor tissue for the immunohistochemistry of p16, PD-L1, and L1CAM. These biomarkers and clinicopathological factors (International Federation of Gynecology and Obstetrics 2009 stage, nodal status, histology, and necrosis on MRI) were analyzed to predict poor response at BT (high-risk clinical target volume [HR-CTV] ≥ 40 cc) at BT) and 5-year local control, pelvic control, and disease-free survival. Interaction between p16, PD-L1, radiation therapy dose (HR-CTV D90), and disease outcomes was investigated. Univariable and multivariable analyses were performed. RESULTS: Two hundred sixty-four patients were included. The median HR-CTV D90 was 89 Gy (86-95). P-16 positive status, PD-L1 > 1%, and L1CAM ≥ 10% was noted in 86.6%, 20.1%, and 17.8% of patients, respectively. P16 negative status (odds ratio, 2.0; 95% CI, 1.0-5.7; P = .04) and necrosis on MRI (odds ratio, 2.1; 95% CI, 1.1-4.3; P < .02) independently predicted for HR-CTV ≥ 40 cc, as did the International Federation of Gynecology and Obstetrics stage and tumor width >5 cm. PD-L1 > 1% was associated with reduced local (82% vs 94%; P = .02) and pelvic control (79% vs 89%; P = .02). HR-CTV D90 < 85 Gy was associated with inferior 5-year local control in p16-positive patients, especially if PD-L1 was coexpressed. On multivariable analysis, PD-L1 > 1% was the only independent factor for 5-year local control (hazard ratio, 3.3; P = .04) and L1CAM ≥ 50% for pelvic control (hazard ratio, 5.5; 95% CI, 1.3-23.3; P = .02). CONCLUSIONS: P16 negative status and tumor necrosis on MRI are independently associated with poor response to chemoradiation, whereas PD-L1 > 1% and L1CAM ≥ 50% have an independent impact on local and pelvic control, suggesting an impact of biomarker expression on outcomes. Further validation is needed.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chopra S, Bosse T, Horeweg N, et al. Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer: BIOEMBRACE. Int J Radiat Oncol Biol Phys. 2024. PMID: 39067486. doi:10.1016/j.ijrobp.2024.07.2316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。